Skip to main content

Heart Attack News (Page 4)

Study IDs Factors Explaining Inequity in CVD Mortality in Cancer Survivors

FRIDAY, July 21, 2023 – Socioeconomic status and insurance explain a considerable proportion of the inequity in cardiovascular disease (CVD) mortality among Black versus White cancer survivors,...

AHA News: A Net Benefit? Here's How Watching Soccer Might Affect Your Health

TUESDAY, July 18, 2023 (American Heart Association News) – Crystal Cuadra-Cutler lives for soccer. And soccer has added a lot to her life. The Gilroy, Calif., resident is a chapter president for the...

New Heart Implant Monitors, Treats -- and Then Dissolves Away

FRIDAY, July 7, 2023 – An experimental implant now under development could serve as a temporary monitor and pacemaker for ailing heart patients – then dissolve away when it’s no longer needed. The s...

Metabolic Surgery Cuts Cardiovascular Events for Obesity, Sleep Apnea

THURSDAY, July 6, 2023 – Metabolic surgery is associated with a lower risk for major adverse cardiovascular events (MACE) in patients with obstructive sleep apnea (OSA) and obesity, according to a...

AHA News: Trim, Fit and 53, His Heart Attack Took Him by Surprise

WEDNESDAY, July 5, 2023 (American Heart Association News) – Ed Frauenheim frequently walked the hilly streets around his San Francisco neighborhood. One summer day, he took long strides to his...

FDA Approves Praluent (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization

PARIS and TARRYTOWN, NY – April 26, 2019 – The U.S. Food and Drug Administration (FDA) has approved Praluent (alirocumab) to reduce the risk of heart attack, stroke, and unstable angina requiring hos...

Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients

PLAINSBORO, N.J., Aug. 25, 2017 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular...

FDA Approves Expanded Indication for Brilinta to Include Long-Term Use in Patients with a History of Heart Attack

Thursday, 3 September 2015 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at a new 60mg dose to be used in patients with a...

FDA Approves Zontivity to Reduce the Risk of Heart Attacks and Stroke

May 8, 2014 – The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore...

FDA Medwatch Alert: Nitroglycerin in 5% Dextrose Injection by Baxter: Recall - Particulate Matter

ISSUE: Baxter International Inc has initiated a voluntary recall of one lot of Nitroglycerin in 5% Dextrose Injection due to particulate matter found in one vial. If infused, particulate matter could...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related drug support groups

lisinopril, metoprolol, aspirin, propranolol, warfarin, Plavix, atenolol, Coumadin, Metoprolol Succinate ER, view more... clopidogrel, Metoprolol Tartrate, Brilinta, valsartan, Lovenox, ramipril, Arthritis Pain, Diovan, ticagrelor, nitroglycerin